NASDAQ:RGNX - REGENXBIO Stock Price, Price Target & More

$37.25 -2.40 (-6.05 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$39.65
Today's Range$35.65 - $40.00
52-Week Range$16.30 - $42.00
Volume816,259 shs
Average Volume457,605 shs
Market Capitalization$1.26 billion
P/E Ratio-15.20
Dividend YieldN/A
Beta-1.15

About REGENXBIO (NASDAQ:RGNX)

REGENXBIO logoREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181

Debt

Debt-to-Equity RatioN/A
Current Ratio11.64%
Quick Ratio11.64%

Price-To-Earnings

Trailing P/E Ratio-15.20
Forward P/E Ratio-15.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.39 million
Price / Sales114.26
Cash FlowN/A
Price / CashN/A
Book Value$5.88 per share
Price / Book6.34

Profitability

EPS (Most Recent Fiscal Year)($2.45)
Net Income$-73,160,000.00
Net Margins-704.02%
Return on Equity-36.48%
Return on Assets-34.17%

Miscellaneous

Employees139
Outstanding Shares31,870,000

How to Become a New Pot Stock Millionaire

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) issued its quarterly earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.20. The biotechnology company earned $2.04 million during the quarter. REGENXBIO had a negative net margin of 704.02% and a negative return on equity of 36.48%. View REGENXBIO's Earnings History.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for REGENXBIO.

What price target have analysts set for RGNX?

7 equities research analysts have issued twelve-month price targets for REGENXBIO's shares. Their forecasts range from $25.00 to $90.00. On average, they expect REGENXBIO's share price to reach $42.7143 in the next twelve months. View Analyst Ratings for REGENXBIO.

What are Wall Street analysts saying about REGENXBIO stock?

Here are some recent quotes from research analysts about REGENXBIO stock:
  • 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (4/17/2018)
  • 2. Chardan Capital analysts commented, "We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options." (12/11/2017)

Who are some of REGENXBIO's key competitors?

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the folowing people:
  • Mr. Kenneth T. Mills, CEO, Pres & Director (Age 43)
  • Mr. Curran M. Simpson, Sr. VP of Technical Operations (Age 56)
  • Mr. Vittal K. Vasista, CFO & Principal Accounting Officer (Age 50)
  • Mr. Patrick J. Christmas II, Sr. VP & Gen. Counsel (Age 47)
  • Mr. Andrew Yost, VP of Corp. Devel.

Has REGENXBIO been receiving favorable news coverage?

Media headlines about RGNX stock have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. REGENXBIO earned a daily sentiment score of 0.17 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.92 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $37.25.

How big of a company is REGENXBIO?

REGENXBIO has a market capitalization of $1.26 billion and generates $10.39 million in revenue each year. The biotechnology company earns $-73,160,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. REGENXBIO employs 139 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]


MarketBeat Community Rating for REGENXBIO (RGNX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about REGENXBIO and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

REGENXBIO (NASDAQ:RGNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for REGENXBIO in the last 12 months. Their average twelve-month price target is $42.7143, suggesting that the stock has a possible upside of 14.67%. The high price target for RGNX is $90.00 and the low price target for RGNX is $25.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.863.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $42.7143$41.1429$43.1667$40.40
Price Target Upside: 14.67% upside23.92% upside22.63% upside19.88% upside

REGENXBIO (NASDAQ:RGNX) Consensus Price Target History

Price Target History for REGENXBIO (NASDAQ:RGNX)

REGENXBIO (NASDAQ:RGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2018Raymond JamesSet Price TargetBuy$45.00LowView Rating Details
4/9/2018Chardan CapitalBoost Price TargetBuy -> Buy$85.00 -> $90.00HighView Rating Details
3/14/2018Morgan StanleyLower Price TargetOverweight -> Overweight$36.00 -> $35.00LowView Rating Details
2/12/2018MizuhoInitiated CoverageNeutral -> Neutral$28.00LowView Rating Details
11/22/2017BarclaysInitiated CoverageOverweight$38.00N/AView Rating Details
10/9/2017Bank of AmericaReiterated RatingBuy$33.00 -> $38.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$25.00HighView Rating Details
11/13/2016Piper JaffrayReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

REGENXBIO (NASDAQ:RGNX) Earnings History and Estimates Chart

Earnings by Quarter for REGENXBIO (NASDAQ:RGNX)

REGENXBIO (NASDAQ:RGNX) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.46 EPS
Next Year EPS Consensus Estimate: $-3.4 EPS

REGENXBIO (NASDAQ RGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$0.02N/AView Earnings Details
3/6/2018Y 2017($0.71)($0.51)$2.04 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.71)($0.67)$1.34 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.81)($0.47)$6.56 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.76)($0.82)$0.46 millionViewListenView Earnings Details
3/7/2017Y 2016($0.75)($0.74)$1.70 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.60)($0.69)$0.13 millionViewN/AView Earnings Details
8/9/2016Q2 2016($0.52)($0.55)$2.38 millionViewN/AView Earnings Details
5/5/2016($0.40)($0.41)$0.39 millionViewN/AView Earnings Details
3/3/2016Q415($0.34)($0.20)$1.23 million$4.40 millionViewN/AView Earnings Details
11/5/2015Q315($0.35)($1.52)$1.10 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

REGENXBIO (NASDAQ:RGNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

REGENXBIO (NASDAQ RGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.00%
Institutional Ownership Percentage: 67.63%
Insider Trading History for REGENXBIO (NASDAQ:RGNX)
Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

REGENXBIO (NASDAQ RGNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Vittal VasistaCFOSell5,000$37.56$187,800.00154,434View SEC Filing  
4/11/2018Patrick J ChristmasSVPSell10,000$39.00$390,000.0011,141View SEC Filing  
4/9/2018Patrick J ChristmasSVPSell10,000$34.00$340,000.0011,141View SEC Filing  
3/26/2018Vittal VasistaCFOSell5,000$30.00$150,000.00157,283View SEC Filing  
3/20/2018Kenneth T MillsInsiderSell10,000$29.55$295,500.00228,530View SEC Filing  
3/13/2018Curran SimpsonSVPSell25,000$33.00$825,000.00View SEC Filing  
2/20/2018Kenneth T MillsInsiderSell10,000$26.56$265,600.00238,530View SEC Filing  
1/22/2018Kenneth T MillsInsiderSell10,000$27.33$273,300.00248,530View SEC Filing  
1/16/2018Vittal VasistaCFOSell5,000$30.16$150,800.00View SEC Filing  
12/22/2017Curran SimpsonSVPSell30,000$33.03$990,900.0069,500View SEC Filing  
12/20/2017Kenneth T MillsInsiderSell10,000$31.75$317,500.00108,530View SEC Filing  
12/19/2017Vittal VasistaCFOSell5,000$30.00$150,000.0087,277View SEC Filing  
12/7/2017Curran SimpsonSVPSell21,890$30.04$657,575.6041,390View SEC Filing  
12/4/2017Curran SimpsonSVPSell110$30.00$3,300.0039,610View SEC Filing  
11/27/2017Curran SimpsonSVPSell2,000$29.31$58,620.0041,500View SEC Filing  
11/20/2017Kenneth T MillsInsiderSell10,000$27.71$277,100.00View SEC Filing  
10/20/2017Kenneth T MillsInsiderSell10,000$32.62$326,200.0098,730View SEC Filing  
10/16/2017Vittal VasistaCFOSell5,000$33.25$166,250.0092,283View SEC Filing  
10/11/2017Donald J Hayden JrDirectorSell20,000$34.95$699,000.00View SEC Filing  
9/27/2017Donald J Hayden JrDirectorSell20,000$32.45$649,000.0020,000View SEC Filing  
9/20/2017Kenneth T MillsInsiderSell10,000$29.33$293,300.00108,630View SEC Filing  
9/18/2017Donald J Hayden JrDirectorSell40,000$28.70$1,148,000.0020,000View SEC Filing  
9/15/2017Vittal VasistaCFOSell5,000$27.39$136,950.0099,594View SEC Filing  
9/8/2017Stephen YooInsiderSell27,342$25.00$683,550.0027,342View SEC Filing  
9/6/2017Stephen YooInsiderSell32,658$25.00$816,450.0031,803View SEC Filing  
9/5/2017Donald J Hayden JrDirectorSell20,000$24.95$499,000.0020,000View SEC Filing  
9/5/2017Kenneth T MillsInsiderSell10,500$25.00$262,500.00118,530View SEC Filing  
8/21/2017Kenneth T MillsInsiderSell6,500$20.05$130,325.00105,500View SEC Filing  
8/15/2017Vittal VasistaCFOSell3,040$21.09$64,113.60103,118View SEC Filing  
7/20/2017Kenneth T MillsInsiderSell6,500$18.66$121,290.00112,000View SEC Filing  
7/17/2017Vittal VasistaCFOSell3,100$19.81$61,411.00108,423View SEC Filing  
6/20/2017Kenneth T MillsInsiderSell6,500$19.68$127,920.00119,396View SEC Filing  
6/15/2017Vittal VasistaCFOSell3,100$18.75$58,125.00107,512View SEC Filing  
4/24/2017Donald J Hayden JrDirectorSell10,000$20.98$209,800.0028,599View SEC Filing  
4/24/2017Kenneth T MillsInsiderSell15,440$20.98$323,931.20126,395View SEC Filing  
4/24/2017Vittal VasistaCFOSell3,100$21.00$65,100.00114,039View SEC Filing  
5/17/2016Fmr LlcInsiderSell18,300$12.41$227,103.00View SEC Filing  
5/16/2016Fmr LlcInsiderSell16,030$11.65$186,749.50View SEC Filing  
5/12/2016Fmr LlcInsiderSell6,711$10.85$72,814.35View SEC Filing  
5/11/2016Fmr LlcInsiderSell25,132$10.36$260,367.52View SEC Filing  
5/9/2016Fmr LlcInsiderSell10,570$9.94$105,065.80View SEC Filing  
5/4/2016Fmr LlcInsiderSell1,896$10.51$19,926.96View SEC Filing  
5/3/2016Fmr LlcInsiderSell6,046$10.76$65,054.96View SEC Filing  
4/29/2016Fmr LlcInsiderSell4,723$10.80$51,008.40View SEC Filing  
4/28/2016Fmr LlcInsiderSell33,196$11.23$372,791.08View SEC Filing  
4/26/2016Fmr LlcInsiderSell9,188$11.19$102,813.72View SEC Filing  
4/22/2016Fmr LlcInsiderSell20,558$11.30$232,305.40View SEC Filing  
4/20/2016Fmr LlcInsiderSell13,189$11.66$153,783.74View SEC Filing  
4/18/2016Fmr LlcInsiderSell18,900$11.75$222,075.00View SEC Filing  
4/14/2016Fmr LlcInsiderSell27,036$11.46$309,832.56View SEC Filing  
9/22/2015James E FlynnInsiderBuy175,000$22.00$3,850,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

REGENXBIO (NASDAQ RGNX) News Headlines

Source:
DateHeadline
REGENXBIO Inc. (RGNX) Given Average Rating of "Buy" by AnalystsREGENXBIO Inc. (RGNX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 23 at 3:34 AM
REGENXBIO (RGNX) Raised to "Buy" at BidaskClubREGENXBIO (RGNX) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 20 at 11:55 AM
Insider Selling: REGENXBIO Inc. (RGNX) CFO Sells 5,000 Shares of StockInsider Selling: REGENXBIO Inc. (RGNX) CFO Sells 5,000 Shares of Stock
www.americanbankingnews.com - April 18 at 7:46 PM
Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical BinaryRounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary
seekingalpha.com - April 17 at 9:33 AM
REGENXBIO (RGNX) Downgraded by Zacks Investment Research to "Sell"REGENXBIO (RGNX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 17 at 8:47 AM
Regenxbio Inc (RGNX) SVP Sells $390,000.00 in StockRegenxbio Inc (RGNX) SVP Sells $390,000.00 in Stock
www.americanbankingnews.com - April 13 at 7:11 PM
How Analysts Rate Regenxbio and Peers in April 2018How Analysts Rate Regenxbio and Peers in April 2018
finance.yahoo.com - April 13 at 4:42 PM
A Look at Regenxbio’s Recent Financial PerformanceA Look at Regenxbio’s Recent Financial Performance
finance.yahoo.com - April 13 at 4:42 PM
What Investors Should Know about Regenxbio’s Research PipelineWhat Investors Should Know about Regenxbio’s Research Pipeline
finance.yahoo.com - April 13 at 4:42 PM
How Regenxbio’s Cash Flows and Valuation Metrics MovedHow Regenxbio’s Cash Flows and Valuation Metrics Moved
finance.yahoo.com - April 13 at 4:42 PM
Chardan Capital Increases Regenxbio (RGNX) Price Target to $55.00Chardan Capital Increases Regenxbio (RGNX) Price Target to $55.00
www.americanbankingnews.com - April 11 at 11:23 PM
Patrick J. Christmas Sells 10,000 Shares of Regenxbio Inc (RGNX) StockPatrick J. Christmas Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - April 11 at 7:09 PM
Regenxbio (RGNX) Given a $45.00 Price Target at Raymond James FinancialRegenxbio (RGNX) Given a $45.00 Price Target at Raymond James Financial
www.americanbankingnews.com - April 11 at 6:13 PM
Regenxbio Inc. (RGNX) PT Raised to $29 at Mizuho Securities on $100M Milestone Related to NVX/AVXSRegenxbio Inc. (RGNX) PT Raised to $29 at Mizuho Securities on $100M Milestone Related to NVX/AVXS
www.streetinsider.com - April 10 at 9:36 AM
How a Rockville company benefits from Novartis $8.7B purchase of a Chicago biotechHow a Rockville company benefits from Novartis' $8.7B purchase of a Chicago biotech
www.bizjournals.com - April 9 at 4:38 PM
AVXS-101AVXS-101
www.benzinga.com - April 9 at 4:38 PM
Regenxbio (RGNX) PT Raised to $90.00Regenxbio (RGNX) PT Raised to $90.00
www.americanbankingnews.com - April 9 at 10:28 AM
REGENXBIO to receive $180M from NAV AAV9 licensee AveXis on Novartis tie-up; shares ahead 21% premarketREGENXBIO to receive $180M from NAV AAV9 licensee AveXis on Novartis tie-up; shares ahead 21% premarket
seekingalpha.com - April 9 at 9:25 AM
Regenxbio (RGNX) Rating Increased to Hold at ValuEngineRegenxbio (RGNX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 1:10 PM
Regenxbio (RGNX) Price Target Raised to $85.00 at Chardan CapitalRegenxbio (RGNX) Price Target Raised to $85.00 at Chardan Capital
www.americanbankingnews.com - March 31 at 7:10 PM
Regenxbio (RGNX) Stock Rating Lowered by BidaskClubRegenxbio (RGNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 30 at 2:18 PM
Regenxbio Inc (RGNX) Given Consensus Rating of "Buy" by AnalystsRegenxbio Inc (RGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 29 at 3:25 AM
Regenxbio Inc (RGNX) CFO Sells $150,000.00 in StockRegenxbio Inc (RGNX) CFO Sells $150,000.00 in Stock
www.americanbankingnews.com - March 28 at 10:46 PM
Insider Selling: Regenxbio Inc (RGNX) Insider Sells 10,000 Shares of StockInsider Selling: Regenxbio Inc (RGNX) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - March 22 at 7:32 PM
Regenxbio (RGNX) Downgraded by BidaskClub to HoldRegenxbio (RGNX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - March 18 at 4:58 PM
Edited Transcript of RGNX earnings conference call or presentation 6-Mar-18 9:30pm GMTEdited Transcript of RGNX earnings conference call or presentation 6-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:08 AM
Regenxbio (RGNX) Upgraded to Buy at Zacks Investment ResearchRegenxbio (RGNX) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 16 at 6:24 AM
Insider Selling: Regenxbio Inc (RGNX) SVP Sells 25,000 Shares of StockInsider Selling: Regenxbio Inc (RGNX) SVP Sells 25,000 Shares of Stock
www.americanbankingnews.com - March 15 at 7:46 PM
Regenxbio (RGNX) PT Lowered to $35.00 at Morgan StanleyRegenxbio (RGNX) PT Lowered to $35.00 at Morgan Stanley
www.americanbankingnews.com - March 14 at 11:45 AM
Regenxbio (RGNX) Upgraded at Zacks Investment ResearchRegenxbio (RGNX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 10 at 9:54 PM
Regenxbio (RGNX) Cut to "Hold" at Zacks Investment ResearchRegenxbio (RGNX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 10 at 2:33 PM
Zacks: Brokerages Expect Regenxbio Inc (RGNX) to Announce -$0.69 EPSZacks: Brokerages Expect Regenxbio Inc (RGNX) to Announce -$0.69 EPS
www.americanbankingnews.com - March 9 at 5:23 PM
Regenxbio (RGNX) Posts  Earnings Results, Beats Estimates By $0.28 EPSRegenxbio (RGNX) Posts Earnings Results, Beats Estimates By $0.28 EPS
www.americanbankingnews.com - March 6 at 7:17 PM
Regenxbio Q4 Earnings OutlookRegenxbio Q4 Earnings Outlook
finance.yahoo.com - March 6 at 4:59 PM
REGENXBIO, Inc. to Host Earnings CallREGENXBIO, Inc. to Host Earnings Call
finance.yahoo.com - March 6 at 4:59 PM
Regenxbio Inc (RGNX) Given Consensus Recommendation of "Buy" by BrokeragesRegenxbio Inc (RGNX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 4 at 3:30 AM
Regenxbio Inc (RGNX) Sees Significant Increase in Short InterestRegenxbio Inc (RGNX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - March 3 at 3:26 AM
Regenxbio Inc (RGNX) Position Lifted by Hudson Bay Capital Management LPRegenxbio Inc (RGNX) Position Lifted by Hudson Bay Capital Management LP
www.americanbankingnews.com - March 1 at 12:04 PM
Ascend Capital LLC Sells 180,988 Shares of Regenxbio Inc (RGNX)Ascend Capital LLC Sells 180,988 Shares of Regenxbio Inc (RGNX)
www.americanbankingnews.com - March 1 at 4:42 AM
REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational HighlightsREGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - February 27 at 5:14 PM
Regenxbio (RGNX) Set to Announce Quarterly Earnings on MondayRegenxbio (RGNX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - February 26 at 3:38 AM
Kenneth T. Mills Sells 10,000 Shares of Regenxbio Inc (RGNX) StockKenneth T. Mills Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - February 22 at 6:46 PM
-$0.71 EPS Expected for Regenxbio Inc (RGNX) This Quarter-$0.71 EPS Expected for Regenxbio Inc (RGNX) This Quarter
www.americanbankingnews.com - February 20 at 11:16 PM
Mizuho Initiates Coverage on Regenxbio (RGNX)Mizuho Initiates Coverage on Regenxbio (RGNX)
www.americanbankingnews.com - February 12 at 8:28 PM
Regenxbio Inc (NASDAQ:RGNX): Financial Strength AnalysisRegenxbio Inc (NASDAQ:RGNX): Financial Strength Analysis
finance.yahoo.com - February 12 at 4:20 PM
BidaskClub Upgrades Regenxbio (RGNX) to BuyBidaskClub Upgrades Regenxbio (RGNX) to Buy
www.americanbankingnews.com - February 10 at 9:24 AM
Regenxbio (RGNX) Reports Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMDRegenxbio (RGNX) Reports Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
www.streetinsider.com - February 9 at 9:23 AM
REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMDREGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
finance.yahoo.com - February 8 at 4:14 PM
REGENXBIO to Participate in Upcoming Investor ConferencesREGENXBIO to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 8 at 8:46 AM
Regenxbio Inc (RGNX) Receives Consensus Rating of "Buy" from AnalystsRegenxbio Inc (RGNX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 7 at 3:24 AM

SEC Filings

REGENXBIO (NASDAQ:RGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

REGENXBIO (NASDAQ:RGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

REGENXBIO (NASDAQ RGNX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.